Erasca, Inc. (ERAS)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
18.03 USD
-1.46
(-7.491%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 18.10 +0.07 (0.388%) ⇧ (Aug. 28, 2026, 7:41 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:48 a.m. EDT
The investment case here is fundamentally broken. The company is burning cash aggressively with negative free cash flow and operating cash flow, while returning nothing to shareholders via dividends. The balance sheet shows significant debt relative to equity, and the return on assets and equity are deeply negative, indicating management is failing to generate value from the capital base. The price action confirms this deterioration; the stock has lost over 90% of its value over the last four years, with the most recent annual period seeing another sharp drop. Despite a 'Buy' recommendation from analysts and a target price significantly higher than the current level, these metrics likely reflect a hope for a clinical trial success or regulatory approval that hasn't materialized yet, rather than current operational reality. The options market is screaming caution, with traders loading up on downside insurance. This is a speculative gamble on a binary event, not a sound investment vehicle. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.225959 |
| AutoETS | 0.252072 |
| AutoARIMA | 0.252074 |
| AutoTheta | 0.404947 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 19.41 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.068 |
| Excess Kurtosis | -0.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.356 |
| Market Cap | 6,306,209,792 |
| Forward P/E | -30.19 |
| Beta | 0.65 |
| Website | https://www.erasca.com |
As of Aug. 22, 2026, 1:48 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes 5.0, 7.5, 10.0) expiring late 2026 and early 2027. While there is some call volume at strikes like 35.0 and 22.5, the overwhelming capital allocation is in put writing and buying, suggesting a consensus view of continued volatility and potential further decline rather than a near-term rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 11.18125 |
| Address1 | 3,115 Merryfield Row |
| Address2 | Suite 300 |
| All Time High | 24.47 |
| All Time Low | 1.01 |
| Ask | 23.47 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 3,175,680 |
| Average Daily Volume3 Month | 4,813,958 |
| Average Volume | 4,813,958 |
| Average Volume10Days | 3,175,680 |
| Beta | 0.652 |
| Bid | 13.86 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.158 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.03 |
| Current Ratio | 8.294 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 19.59 |
| Day Low | 18.0 |
| Debt To Equity | 12.356 |
| Display Name | Erasca |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | -147,743,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -44.624 |
| Enterprise Value | 6,592,838,144 |
| Eps Current Year | -0.96889 |
| Eps Forward | -0.59727 |
| Eps Trailing Twelve Months | -0.95 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 18.0224 |
| Fifty Day Average Change | 0.0076007843 |
| Fifty Day Average Change Percent | 0.00042174096 |
| Fifty Two Week Change Percent | 1,118.125 |
| Fifty Two Week High | 24.28 |
| Fifty Two Week High Change | -6.25 |
| Fifty Two Week High Change Percent | -0.2574135 |
| Fifty Two Week Low | 1.33 |
| Fifty Two Week Low Change | 16.7 |
| Fifty Two Week Low Change Percent | 12.556391 |
| Fifty Two Week Range | 1.33 - 24.28 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,626,442,200,000 |
| Float Shares | 242,902,738 |
| Forward Eps | -0.59727 |
| Forward P E | -30.187353 |
| Free Cashflow | -210,460,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 103 |
| Fullday Change | -1.46 |
| Fullday Change Percent | -7.49102 |
| Fullday Price | 18.1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.09476 |
| Held Percent Institutions | 0.85767 |
| Implied Shares Outstanding | 349,762,035 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California. |
| Long Name | Erasca, Inc. |
| Market | us_market |
| Market Cap | 6,306,209,792 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_595471999 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -287,223,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,822,108,492 |
| Number Of Analyst Opinions | 10 |
| Open | 19.25 |
| Operating Cashflow | -98,022,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 858 465 6511 |
| Post Market Change | 0.069999695 |
| Post Market Change Percent | 0.3882401 |
| Post Market Price | 18.1 |
| Post Market Time | 1,787,960,488 |
| Previous Close | 19.49 |
| Price Eps Current Year | -18.608925 |
| Price Hint | 2 |
| Price To Book | 15.569949 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.08 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.6 |
| Region | US |
| Regular Market Change | -1.46 |
| Regular Market Change Percent | -7.49102 |
| Regular Market Day High | 19.59 |
| Regular Market Day Low | 18.0 |
| Regular Market Day Range | 18.0 - 19.59 |
| Regular Market Open | 19.25 |
| Regular Market Previous Close | 19.49 |
| Regular Market Price | 18.03 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 2,887,317 |
| Return On Assets | -0.21393 |
| Return On Equity | -0.78249 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 349,762,035 |
| Shares Percent Shares Out | 0.088199995 |
| Shares Short | 30,847,289 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 30,766,629 |
| Short Name | Erasca, Inc. |
| Short Percent Of Float | 0.097600006 |
| Short Ratio | 7.32 |
| Source Interval | 15 |
| State | CA |
| Symbol | ERAS |
| Target High Price | 30.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 23.5 |
| Target Median Price | 23.0 |
| Total Cash | 268,737,984 |
| Total Cash Per Share | 0.768 |
| Total Debt | 44,714,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.95 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 12.410475 |
| Two Hundred Day Average Change | 5.619526 |
| Two Hundred Day Average Change Percent | 0.45280507 |
| Type Disp | Equity |
| Volume | 2,887,317 |
| Website | https://www.erasca.com |
| Zip | 92,121 |